Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
Verapamil may warrant testing to overcome adriamycin resistance; leaves open clinical efficacy in ovarian cancer.
The effectiveness of adriamycin in the treatment of ovarian cancer and other human tumors has been limited by the development of drug resistance. Verapamil, a calcium channel blocking agent, completely reversed adriamycin resistance in human ovarian cancer cells with moderate (three- to sixfold) degrees of resistance and partially reversed resistance in highly (150-fold) resistant cells. The potentiating effect of verapamil was due to inhibition of adriamycin efflux in the resistant cells. These results have led to a clinical trial of adriamycin and verapamil in refractory ovarian cancer patients.
No takes yet. Share an insight, caveat, or question.
Rogan et al. (1984) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: